BR100 Decreased By (-0.25%)
BR30 Decreased By (-0.64%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.80 Decreased By ▼ -0.23 (-3.81%)
BML 58.03 Increased By ▲ 5.28 (10.01%)
BOP 33.85 Decreased By ▼ -0.40 (-1.17%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.77 Decreased By ▼ -0.57 (-4.62%)
FCCL 53.35 Decreased By ▼ -0.54 (-1%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.05 Decreased By ▼ -0.06 (-0.74%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.19 Decreased By ▼ -0.86 (-0.98%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.31 Increased By ▲ 0.37 (0.93%)
PIAHCLA 26.10 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.09 Decreased By ▼ -0.23 (-1.33%)
PPL 228.40 Decreased By ▼ -4.38 (-1.88%)
PRL 34.59 Decreased By ▼ -0.36 (-1.03%)
PTC 67.35 Decreased By ▼ -0.21 (-0.31%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.90 Decreased By ▼ -0.27 (-0.99%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.29 Increased By ▲ 0.53 (6.05%)
TREET 24.59 Increased By ▲ 0.05 (0.2%)
TRG 71.69 Decreased By ▼ -0.06 (-0.08%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
اردو
Android App
Print Edition Dollar to PKR
Budget 2026-27 Iran-US war Petrol Prices Gold Rates Podcasts PSX Notices
Topic

Eli Lilly and Co

Lilly hit by staff accusations, FDA scrutiny at COVID drug factories

Lilly hit by staff accusations, FDA scrutiny at COVID drug factories

Published 05 May, 2021 06:50pm
  • The source, who spoke on condition of anonymity, said the findings involved the production of drugs including Lilly's COVID-19 therapy, whose use in the United States is funded by the federal government.
  • Separately, FDA inspectors in March identified numerous manufacturing lapses at a second Lilly facility in Indianapolis that bottles the COVID-19 therapy and other drugs.
Eli Lilly to supply 400,000 tablets of its COVID-19 treatment to India

Eli Lilly to supply 400,000 tablets of its COVID-19 treatment to India

Published 04 May, 2021 06:13pm
  • With 3.45 million active cases, India recorded 357,229 new infections over the last 24 hours, while deaths rose 3,449 for a toll of 222,408, health ministry data showed. Experts say actual numbers could be five to 10 times higher, however.
  • The drugmaker said it will work urgently to increase the supply multifold over the coming weeks.
Eli Lilly profit forecast trimmed as vaccines dent US demand for COVID-19 drugs

Eli Lilly profit forecast trimmed as vaccines dent US demand for COVID-19 drugs

Published 27 Apr, 2021 08:23pm
  • Nearly 30% of the US population has been vaccinated against COVID-19, hitting demand for antibody drugs that already suffered from slower-than-expected uptake by hospitals.
  • Sales of other high-profile Lilly drugs also fell short of Wall Street expectations and its shares fell 3% to $181.64 in morning trading.
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

Published 16 Apr, 2021 05:45pm
  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Eli Lilly to focus on selling COVID-19 antibody drug combination

Eli Lilly to focus on selling COVID-19 antibody drug combination

Published 12 Apr, 2021 09:15pm
  • Lilly and the US government have agreed to modify their existing agreement to enable the supply of etesevimab to complement doses of bamlanivimab the US government had already purchased, the drugmaker said.
  • The earlier supply agreement for bamlanivimab has been terminated and cancels the remaining 350,856 doses of bamlanivimab that were scheduled to be delivered by the end of March 2021.
Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial

Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial

Updated 13 Mar, 2021 09:08pm
  • The drug, donanemab, also showed positive trends that failed to reach statistical significance on a range of secondary trial goals, the company said, providing details for the first time.
  • The ability to carry out activities like dressing and eating is often impacted by Alzheimer's disease, which reduces cognitive ability like memory and language.
Lilly says CFO resigns after investigation into inappropriate relationship

Lilly says CFO resigns after investigation into inappropriate relationship

Updated 09 Feb, 2021 11:32pm
  • The drugmaker said it immediately hired external counsel to conduct an independent probe after it was made aware of the allegations.
  • Lilly said the behavior exhibited poor judgment by Smiley. The company would not give further details on the communications or the number of employees involved.
Eli Lilly profit rises 41.5pc as COVID-19 drug lifts sales

Eli Lilly profit rises 41.5pc as COVID-19 drug lifts sales

Published 29 Jan, 2021 06:00pm
  • The company reported worldwide revenue of $871.2 million in the fourth quarter from the therapy, bamlanivimab.
  • Net earnings rose to $2.12 billion, or $2.32 per share, in the fourth quarter ended Dec. 31 from $1.50 billion, or $1.64 per share, a year earlier.
Lilly antibody combo therapy cuts risk of COVID-19 deaths

Lilly antibody combo therapy cuts risk of COVID-19 deaths

Published 26 Jan, 2021 08:02pm
  • Lilly said the study has met both the main goal of reducing risk of death and hospitalization and all key secondary goals.
  • The ongoing trial will enroll up to 3,300 participants across all treatment groups, Lilly said.
Lilly says Alzheimer's drug slows clinical decline in mid-stage trial

Lilly says Alzheimer's drug slows clinical decline in mid-stage trial

Published 11 Jan, 2021 06:51pm
  • The drug is an antibody designed to remove clumps of the Alzheimer's-related protein beta amyloid from the brain.
  • Lilly said the mid-stage trial of 272 patients met its main goal of showing a statistically significant change in clinical decline over 18 months.
Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial

Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial

Published 09 Oct, 2020 12:49am
  • Lilly said the effect was most pronounced in patients on oxygen therapy, according to data from a US government-backed trial.
  • Lilly said 5.1% of patients on the drug combination died after 29 days versus 7.8% patients given remdesivir,
Eli Lilly applies for emergency use of antibody drug for COVID-19

Eli Lilly applies for emergency use of antibody drug for COVID-19

Published 08 Oct, 2020 12:28am
  • The drugmaker said its two-antibody cocktail helped reduce viral levels more than the single antibody treatment had in a prior study.
  • We believe that Lilly's data provides some real evidence that the combo mAb (monoclonal antibody) approach may provide meaningful clinical benefits.
Lilly, Amgen partner to manufacture potential COVID-19 drugs

Lilly, Amgen partner to manufacture potential COVID-19 drugs

Published 17 Sep, 2020 06:23pm
  • Antibody treatments work by recognizing and locking onto foreign invaders to prevent infection of healthy cells.
  • We are impressed with Lilly's data, in particular the reduction in hospitalizations, and are enthusiastic about the potential for these neutralizing antibodies as a therapeutic for COVID-19.
Loading...